Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Terminology == The term accepted point mutation was initially used to describe the mutation phenomenon. However, the acronym PAM was preferred over APM due to readability, and so the term point accepted mutation is used more regularly. Because the value
1.7 L (1,686 cc) 4EE1-T, I4 8-valve SOHC, turbo-diesel, 82–88 PS (60–65 kW; 81–87 hp) / 167–168 N⋅m (123–124 lb⋅ft) (1995–1998) 2.0 L (1,998 cc) RF, I4 8-valve SOHC, 71 PS (52 kW; 70 hp) / 128 N⋅m (94 lb⋅ft) (1996–1999)
== External links == Protein-DNA binding: data, tools & models (annotated list, constantly updated) Abalone tool for modeling DNA-ligand interactions. DBD database of predicted transcription factors Uses a curated set of DNA-binding domains to predict transcription factors in all completely sequenced genomes DNA-Binding+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Appendix: Download surveys / evaluations == The AIDA developers have undertaken a range of surveys and evaluations of usage of the AIDA diabetes simulator — to better understand who is downloading the program, and why. One initial study analysed data from 1,360 downloads of the AIDA software. The intended goals of the survey were: (i) to establish the feasibility of using the Internet for auditing and surveying diabetes software users; (ii) to identify the proportion of people with diabetes and their relatives who are actually making use of the program; and (iii) to establish certain technical details about downloaders' computer setups to facilitate the distribution of upgrades to the software. 1,360 responses were received over an 8-month period (from November 1999 to July 2000). During the corresponding period 3,821 actual downloads of the software were independently logged at the Website — giving a response rate to this survey of 35.6%. Responses were received from participants in 67 countries — although over half of these (n=730, 54%) originated from the US and UK. 762 responses (56%) were received from people with diabetes and 184 (13.5%) from relatives of patients, with lesser numbers from doctors, students, diabetes educators, nurses, pharmacists, and other end users. Useful technical information about computers and operating systems being used were also obtained. The initial study established the feasibility of using the Internet to survey, at no real cost, a large number of medical software downloaders / users.
In the experiments about atomic events we have to do with things and facts, with phenomena that are just as real as any phenomena in daily life. But atoms and the elementary particles themselves are not as real; they form a world of potentialities or possibilities rather than one of things or facts ... The probability wave ... mean[s] tendency for something. It's a quantitative version of the old concept of potentia from Aristotle's philosophy. It introduces something standing in the middle between the idea of an event and the actual event, a strange kind of physical reality just in the middle between possibility and reality. A hylomorphic interpretation of Bohmian mechanics has been suggested, in which the cosmos is a single substance that is composed of both material particles and a substantial form. There is also a hylomorphic interpretation of the collapse of the wave function.
Sources: en.wikipedia.org
It is then lowered by a strong rope over an outcrop of coral and the boat trawls over the coral causing it to break off and be caught in the netting. The device is then drawn to the surface by the boat crew.
=== Diffusive === Some materials may merge at the joint by diffusion. This may occur when the molecules of both materials are mobile and soluble in each other. This would be particularly effective with polymer chains where one end of the molecule diffuses into the other material. It is also the mechanism involved in sintering. When metal or ceramic powders are pressed together and heated, atoms diffuse from one particle to the next. This joins the particles into one.
gastrin-34 ("big gastrin") gastrin-17 ("little gastrin") gastrin-14 ("minigastrin") Also, pentagastrin is an artificially synthesized, five amino acid sequence identical to the last five amino acid sequence at the C-terminus end of gastrin. The numbers refer to the amino acid count.
=== Enlarged prostate === Flutamide has been studied in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate) in men in several clinical studies. It has been found to reduce prostate volume by about 25%, which is comparable to the reduction achieved with the 5α-reductase inhibitor finasteride. Unfortunately, it has been associated with side effects in these studies including gynecomastia and breast tenderness (in about 50% of patients), gastrointestinal disturbances such as nausea, diarrhea, and flatulence, and hepatotoxicity, although sexual function including libido and erectile potency were maintained.
In reaction, APHIS introduced more strict regulations for pharming field trials in the US in 2003. In 2005, Anheuser-Busch threatened to boycott rice grown in Missouri because of plans by Ventria Bioscience to grow pharm rice in the state. A compromise was reached, but Ventria withdrew its permit to plant in Missouri due to unrelated circumstances. The industry has slowly recovered, by focusing on pharming in simple plants grown in bioreactors and on growing GM crops in greenhouses. Some companies and academic groups have continued with open-field trials of GM crops that produce drugs. In 2006 Dow AgroSciences received USDA approval to market a vaccine for poultry against Newcastle disease, produced in plant cell culture – the first plant-produced vaccine approved in the U.S.
Sources: en.wikipedia.org
At atmospheric levels of ambient CO2 the table indicates that the solution will be slightly alkaline with a maximum CaCO3 solubility of 47 mg/L. As ambient CO2 partial pressure is reduced below atmospheric levels, the solution becomes more and more alkaline. At extremely low PCO2, dissolved CO2, bicarbonate ion, and carbonate ion largely evaporate from the solution, leaving a highly alkaline solution of calcium hydroxide, which is more soluble than CaCO3. For PCO2 = 10−12 atm, the [Ca2+][OH−]2 product is still below the solubility product of Ca(OH)2 (8×10−6). For still lower CO2 pressure, Ca(OH)2 precipitation will occur before CaCO3 precipitation. As ambient CO2 partial pressure increases to levels above atmospheric, pH drops, and much of the carbonate ion is converted to bicarbonate ion, which results in higher solubility of Ca2+. The effect of the latter is especially evident in day-to-day life of people who have hard water. Water in aquifers underground can be exposed to levels of CO2 much higher than atmospheric. As such, water percolates through calcium carbonate rock, the CaCO3 dissolves according to one of the trends above. When that same water then emerges from the tap, in time, it comes into equilibrium with CO2 levels in the air by outgassing its excess CO2. The calcium carbonate becomes less soluble as a result, and the excess precipitates as lime scale. This same process is responsible for the formation of stalactites and stalagmites in limestone caves.
Cardiology Clinical genetics Clinical pharmacology Endocrinology Gastroenterology and hepatology General medicine Geriatric medicine Haemotology Immunology and allergy Infectious diseases Medical oncology Nephrology Neurology Nuclear medicine Respiratory and sleep medicine Rheumatology
{\displaystyle n_{\mathrm {A} }=n_{\mathrm {B} }{\frac {R_{\mathrm {B} }-R_{\mathrm {AB} }}{R_{\mathrm {AB} }-R_{\mathrm {A} }}}\times {\frac {x(^{j}\mathrm {A} )_{\mathrm {B} }}{x(^{j}\mathrm {A} )_{\mathrm {A} }}}}
== External links == WHO: Good Distribution Practices (GDP) for Pharmaceutical Products Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03) Counterfeit Drugs (FDA) Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (FDA) GDP Guidelines of 7 March 2013 (Eudralex) Guidelines on Good Distribution Practice (NPCB/Malaysia) GDP Guidelines of 7 March 2013 (Eudralex) How to become pharmaceutical distributor
One interview in 2015 with the then Director of the White House Office of National Drug Control Policy under the Obama administration, Michael Botticelli, where he states that because opioid users are predominantly 'white and middle class', they "know how to call a legislator, [and] fight with their insurance company." In October 2017, Marino withdrew his nomination after it was reported that his relationship with the drug industry might be a conflict of interest. In July 2017, FDA commissioner Scott Gottlieb stated that for the first time, pharmacists, nurses, and physicians would have training made available on appropriate prescribing of opioid medicines, because opioid addiction had become the "FDA's biggest crisis". Trump nominated his then deputy chief-of-staff, James Carroll as the acting director of the Office of National Drug Control Policy in 2018. In January 2019, Carroll was approved by the Senate. In April 2017, the Department of Health and Human Services announced their "Opioid Strategy" consisting of five aims:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.